Monitor for future announcements regarding the reverse stock split ratio or execution of the note conversion, as these could significantly impact share price and trading dynamics given the company's small market cap.
Price Chart
Executive Summary
Jaguar Health's stockholders approved a series of capital structure proposals including increasing authorized common shares from 298 million to 500 million, authorizing two potential reverse stock splits (1-for-15 to 1-for-150), and approving the issuance of shares for a $10.81 million promissory note. The share increase is immediately effective, while reverse split decisions remain at the board's discretion.
Key Facts
- Authorized common shares increased from 298,000,000 to 500,000,000
- Total authorized shares increased from 352,475,074 to 554,475,074
- Stockholders approved two potential reverse stock splits (1-for-15 to 1-for-150) at board's discretion
- Approved issuance of shares for $10,810,000 promissory note to Streeterville Capital
- Special meeting held on April 20, 2026 with 7,181,767 shares represented
Financial Impact
The share authorization increase provides flexibility for future fundraising or acquisitions. The $10.81 million note conversion represents approximately 216% of current market cap ($5M). Reverse splits remain potential future actions.
Risk Factors
- Potential significant dilution from converting the $10.81 million note into shares
- Reverse stock split could reduce liquidity and increase volatility
- Large increase in authorized shares without immediate use raises potential overhang concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-165120 |
| Document: d10648dex31.htm | 0001193125-26-165120 |
| Document: d10648dex991.htm | 0001193125-26-165120 |
| Document: 0001193125-26-165120-index-headers.html | 0001193125-26-165120 |
| Document: 0001193125-26-165120-index.html | 0001193125-26-165120 |
| Document: 0001193125-26-165120.txt | 0001193125-26-165120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | S-3 | $2.04 | awaiting T+60 | — | $2.24 (−9.80%) |
Oct 8, 2026 19d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.24 (+53.24%) |
Oct 5, 2026 22d ago | 8-K | $4.73 | awaiting T+60 | — | $2.24 (+52.64%) |
Sep 28, 2026 29d ago | 8-K | $6.02 | awaiting T+60 | — | $2.24 (+62.79%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.24 (+70.91%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.24 (+68.27%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.24 (+68.27%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.24 (−93.50%) |
Sep 15, 2026 6w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.24 (−897.33%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.24 (+78.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers